19619998

Source:http://linkedlifedata.com/resource/pubmed/id/19619998

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0155877, umls-concept:C0966225, umls-concept:C1280519, umls-concept:C2603343, umls-concept:C2887459
pubmed:issue	11
pubmed:dateCreated	2009-10-5
pubmed:abstractText	To evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8908438
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1532-3064
pubmed:author	pubmed-author:AbrahamII, pubmed-author:BrusselleGG, pubmed-author:DelobbeAA, pubmed-author:DupontLL, pubmed-author:GurdainSS, pubmed-author:HermannDD, pubmed-author:LecomtePP, pubmed-author:LeeC SCS, pubmed-author:LouisRR, pubmed-author:MacDonaldKK, pubmed-author:MichilsAA, pubmed-author:PiletteCC, pubmed-author:SongMM, pubmed-author:Van de MaeleBB, pubmed-author:VancayzeeleSS
pubmed:issnType	Electronic
pubmed:volume	103
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1633-42
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19619998-Adolescent, pubmed-meshheading:19619998-Adult, pubmed-meshheading:19619998-Aged, pubmed-meshheading:19619998-Aged, 80 and over, pubmed-meshheading:19619998-Anti-Asthmatic Agents, pubmed-meshheading:19619998-Antibodies, Anti-Idiotypic, pubmed-meshheading:19619998-Antibodies, Monoclonal, pubmed-meshheading:19619998-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19619998-Asthma, pubmed-meshheading:19619998-Belgium, pubmed-meshheading:19619998-Child, pubmed-meshheading:19619998-Female, pubmed-meshheading:19619998-Forced Expiratory Volume, pubmed-meshheading:19619998-Humans, pubmed-meshheading:19619998-Male, pubmed-meshheading:19619998-Middle Aged, pubmed-meshheading:19619998-Prospective Studies, pubmed-meshheading:19619998-Quality of Life, pubmed-meshheading:19619998-Severity of Illness Index, pubmed-meshheading:19619998-Treatment Outcome, pubmed-meshheading:19619998-Young Adult
pubmed:year	2009
pubmed:articleTitle	"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
pubmed:affiliation	Department of Respiratory Medicine, Ghent University Hospital and Ghent University, Belgium.
pubmed:publicationType	Journal Article, Multicenter Study, Evaluation Studies